XORTX Therapeutics (XRTX) Amortizatization of Intangibles (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Amortizatization of Intangibles came in at $3460.0 in Q1 2026, down 46.94% YoY from $6521.0 in Q1 2025, and down 96.25% on a QoQ basis from $92308.0 in Q4 2025.
XORTX Therapeutics (XRTX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Amortizatization of Intangibles data on file, last reported at $3460.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 46.94% year-over-year to $3460.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109054.0 (down 2.55% YoY) and the FY2025 annual result came in at $112115.0, down 4.4% from the prior year.
- Amortizatization of Intangibles fell to $3460.0 in Q1 2026, from $92308.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $92835.0 in Q4 2024 to a low of -$1862.0 in Q3 2023.
- A 5-year average of $25269.0 and a median of $6789.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 1191.36% in 2023, down 106.71% in 2023.
- Tracing XRTX's Amortizatization of Intangibles over 5 years: stood at $21544.9 in 2022, then jumped by 267.25% to $79123.0 in 2023, then increased by 17.33% to $92835.0 in 2024, then dropped by 0.57% to $92308.0 in 2025, then sank by 96.25% to $3460.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $3460.0 (Q1 2026), $92308.0 (Q4 2025), and $6497.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 3,460.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,460.00 |
| Mar 31, 2026 | 3,460.00 |
| Dec 31, 2025 | 92,308.00 |
| Dec 31, 2025 | 92,308.00 |
| Sep 30, 2025 | 6,497.00 |
| Sep 30, 2025 | 6,497.00 |
| Jun 30, 2025 | 6,789.00 |
| Jun 30, 2025 | 6,789.00 |
| Mar 31, 2025 | 6,521.00 |
| Mar 31, 2025 | 6,521.00 |
| Dec 31, 2024 | 92,835.00 |
| Dec 31, 2024 | 92,835.00 |
| Sep 30, 2024 | 6,389.00 |
| Sep 30, 2024 | 6,389.00 |
| Jun 30, 2024 | 6,164.00 |
| Jun 30, 2024 | 6,164.00 |
| Mar 31, 2024 | 11,886.00 |
| Mar 31, 2024 | 11,886.00 |
| Dec 31, 2023 | 79,123.00 |
| Dec 31, 2023 | 79,123.00 |